The company's diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza, and other programs to potentially treat ornithine transcarbamylase deficiency, and cystic fibrosis, along with partnered programs including glycogen storage disease type III, and hepatitis B virus.

In September 2022, the US company was awarded up to $63.2 million from the USA's Biomedical Advanced Research and Development Authority to support preclinical work, manufacturing and nonclinical safety studies.